Video

Dr. Horn on the Role of Mobocertinib in NSCLC

Leora Horn, MD, MSc, FRCPC, discusses the role of mobocertinib in patients with non​–small cell lung cancer.

Leora Horn, MD, MSc, FRCPC, associate professor of cancer research, Vanderbilt Ingram Cancer Center, associate professor of medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, discusses the role of mobocertinib (TAK-788) in patients with non​–small cell lung cancer (NSCLC).

Mobocertinib is an EGFR TKI that is developed for the treatment of patients with EGFR exon 20–mutant and HER2-mutant NSCLC, says Horn.

Notably, minimal data are available with regard to patients with exon 20 insertions because it is a rare mutation that, historically, has not been responsive to first- or second-generation EGFR TKIs, Horn explains.

However, data compiled from Flat​iron Health proved beneficial in terms of comparing the responses of patients with exon 20 mutation​s who received traditional therapies with those ​who received mobocertinib on the phase 1/2 study (NCT02716116), Horn concludes.

Related Videos
Nicolas Girard, MD
Sally Lau, MD
Andrea Wolf, MD, MPH
Jacob Sands, MD
Marina Chiara Garassino, MD
Nicolas Girard, MD
Benjamin Besse, MD, PhD, director, clinical research, Gustave Roussy Institute; professor, medical oncology, Paris-Saclay University
Nicolas Girard, MD
Cathy Eng, MD, FACP, FASCO
Shirish M. Gadgeel, MD